Advanced Enzyme Technologies Ltd.

ADVENZYMESNSEHealthcarePharmaceuticals & DrugsSmall Cap

₹373.7

▲ 0.08%

—

Composite

The company is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (R&D) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-effective unique and innovative solutions, thereby enabling their customers to develop superior products and processes. The company products assist its customers in making most of their resources, optimizing their processes, improving their product quality, saving their time and money while also mitigating the impact on the environment. It supplies these value-added and eco-safe enzyme products to diverse end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although, the company has the capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, their major focus is on developing enzymes through microbial fermentation.

www.advancedenzymes.comSector: HealthcareIndustry: Pharmaceuticals & Drugs

Q-DITS fundamental score

—Composite

Growth

Profitability

Valuation

Quality

Solvency

Earnings

Key metrics

MCap

₹4.2K Cr

TTM PE

24.8x

Industry PE

38.2x

TTM EPS

₹15.07

Book Value

₹145.74

Face Value

₹2

Div Yield

0.36%

PEG

1.79x

2.2x

ROE

9.8%

ROCE

13.8%

EBITDA mgn

35.9%

D/E

0.02

Int. Cover

41.4x

Curr. Ratio

9.09x

EPS

₹11.72

Growth — CAGR across horizons

Metric	1Y	3Y	5Y	10Y
Net Sales	17.1%	11.3%	8.2%	9.4%
EBITDA	17.8%	13.6%	-0.2%	5.2%
Net Profit	22.2%	13.8%	1.9%	7.4%

Score snapshot

Piotroski

5/9

Altman Z

2.15

Quality

72.4

Growth

27.9

Valuation

—

Earn. Qual

68.3

PEAD

SURGE

Revenue, profitability & returns

Revenue & Net Profit (₹ Cr)

RevenueNet Profit

Margins (%)

EBITDA%PAT%

Return ratios (%)

ROEROCEROA

Annual financials — last 10 years

Tap any row to see its trend

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Trend
›RevenueCr	294	329	391	420	444	502	529	541	624	637	↑
›EBITDACr	135	154	166	188	209	241	209	179	227	229	↑
›EBITDA margin	45.6%	45%	42%	44.9%	47.1%	48.5%	39.4%	33.8%	38.8%	35.9%	↓
›Net profitCr	77	93	94	116	133	151	124	104	137	134	↓
›PAT margin	25.2%	27.1%	23.6%	27.6%	30%	30.4%	23.3%	19.2%	21.9%	21%	↓
›EPS₹	₹6.97	₹8.2	₹8.08	₹9.95	₹11.58	₹13.06	₹10.7	₹9.45	₹11.92	₹11.72	↓
›Revenue growth	31.7%	12%	18.9%	7.3%	5.8%	13%	5.5%	2.1%	15.4%	2.1%	↓
›PAT growth	48.1%	21.1%	0.7%	23.9%	14.8%	13.7%	-18.2%	-16.1%	31.9%	-2.2%	↓
›ROE	31.3%	25.1%	18.3%	18.8%	17.6%	16.8%	12%	8.9%	10.7%	9.8%	↓
›ROCE	35.7%	31.5%	25.9%	25%	23.2%	22.9%	16.7%	12.3%	14.8%	13.8%	↓
›ROA	17.8%	18%	14.3%	15.1%	15%	14.3%	10.3%	7.8%	9.3%	8.6%	↓
›P/E	0x	10.1x	26.4x	18.4x	12.4x	26.4x	26.4x	24.5x	29.2x	23.8x	↓
›P/B	0x	9.9x	4.3x	3x	1.9x	4x	2.9x	2.1x	2.9x	2.2x	↓
›D/E	0.4	0.1	0.1	0.1	0	0	0	0	0	0	↓
›Current ratio	1.3x	2.2x	2.1x	4.3x	6.3x	7.6x	10x	9.3x	7.6x	9.1x	↑
›Interest cover	16x	31.9x	16.3x	32.1x	44.9x	82.8x	58.9x	41.4x	46.6x	41.4x	↓

Quarterly results

Tap any row to see its trend

Metric	2023-12	2024-03	2024-06	2024-09	2024-12	2025-03	2025-06	2025-09	2025-12	2026-03	Trend
›RevenueCr	161	158	155	146	169	167	186	185	172	203	↑
›Rev growth YoY	13.2%	13.8%	4.9%	-7.4%	5.1%	5.9%	20.3%	26.3%	1.7%	21.6%	↑
›EBITDACr	54	55	51	42	55	46	56	60	49	63	↑
›EBITDA margin	33.4%	35.1%	33.1%	29%	32.7%	27.3%	30.4%	32.5%	28.7%	31.1%	↑
›Net profitCr	43	30	35	33	39	27	40	45	43	45	↑
›PAT growth YoY	52.3%	-7%	19.1%	-5.1%	-8.5%	-10.5%	15.6%	34%	11.1%	69.3%	↑
›EPS₹	₹3.74	₹2.53	₹3.05	₹2.94	₹3.36	₹2.37	₹3.57	₹3.87	₹3.8	₹3.84	↑

Balance sheet — last 10 years (₹ Cr)

Tap any row to see its trend

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend
›Shareholders' equityCr	464	559	679	840	971	1,089	1,235	1,324	1,421	1,632	↑
›ReservesCr	441	534	653	814	946	1,066	1,213	1,299	1,394	1,610	↑
›Total borrowingsCr	0	0	0	0	0	0	0	0	0	0	—
›InvestmentsCr	10	10	123	141	140	124	377	423	511	0	↓
›Total assetsCr	509	607	718	886	1,048	1,168	1,307	1,395	1,491	1,839	↑
›Current assetsCr	138	211	282	376	516	604	722	810	880	1,044	↑
›Current liabilitiesCr	62	99	65	60	68	60	78	106	97	107	↑
›Trade payablesCr	11	17	10	10	15	18	24	16	17	40	↑
›Gross blockCr	445	561	586	681	756	806	868	902	966	276	↓

Cash flow statement (₹ Cr)

Tap any row to see its trend

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Trend
›Operating CF (CFO)Cr	107	116	129	141	163	122	140	141	143	157	↑
›Investing CF (CFI)Cr	-60	-78	-125	-44	-26	-4	-298	-65	-89	-74	↑
›Financing CF (CFF)Cr	-65	-2	-43	-39	-26	-48	-26	-59	-73	-70	↑
›Net cash changeCr	-18	36	-39	58	111	70	-184	17	-19	12	↑
›Closing cashCr	8	61	23	83	192	267	96	114	94	109	↑

Cash flow components

CFO · CFI · CFF (₹ Cr)

CFOCFICFF

Q-DITS scorecard

Composite score

—

Quality (25%)72.4

Growth (25%)27.9

Valuation (20%)—

Piotroski (15%)56

Earnings Quality (10%)68.3

Momentum (5%)—

Weighted blend, rescaled to the components available for this stock.

Piotroski F-Score

5/9

✓ROA positiveROA 8.55%

✓CFO positiveCFO ₹156.78 Cr

✗ROA improving9.34% → 8.55%

✓CFO > PAT (low accruals)CFO 156.78 vs PAT 133.97

✓Leverage decreasedD/E 0.02 → 0.02

✓Liquidity improvedCR 7.61 → 9.09

✗No share dilutionEPS 11.92 → 11.72

✗Margin improvedEBITDA mgn 38.79% → 35.88%

✗Asset turnover upAsset TO 0.43 → 0.41

Altman Z-Scoregrey

2.15

0.51

0.875

0.104

0.888

0.346

>2.9 safe · 1.23–2.9 grey · <1.23 distress

Quality

72.4/100

ROE

9.8%

ROCE

13.8%

Margin

21%

Debt

Int. cover

41.4x

Growth

27.9/100

Revenue 3Y

11.3%

Profit 3Y

13.8%

EPS

-1.7%

Valuation

N/A

—

EV/EBITDA

—

Earnings quality

68.3/100

CFO₹157 Cr

PAT₹134 Cr

Accrual ratio-0.012

CFO/PAT1.17x

PEAD · SURGE

+2 / +2

Revenue SUE1.28

EPS SUE1.13

Latest quarter2026-03

Rev growth YoY21.6%

Shareholding pattern

Promoter43.3%

FII/FPI25.5%

DII5.4%

Public56.7%

Tap any row to see its trend

Metric	2024-03	2024-06	2024-09	2024-12	2025-03	2025-06	2025-09	2025-12	2026-03	Trend
›Promoter	43.5%	43%	43%	42.9%	43.1%	43.1%	43.1%	43%	43.3%	↑
›FII / FPI	23%	12%	12.6%	12.6%	11.9%	23.5%	25.4%	25.9%	25.5%	↓
›DII	7.6%	8.1%	8%	8.2%	8.2%	8.5%	6.4%	5.5%	5.4%	↓
›Public / Retail	56.5%	57%	57.1%	57.1%	56.9%	56.9%	56.9%	57%	56.7%	↓
›Promoter pledge	0%	0%	0%	0%	0%	0%	0%	0%	0%	—

Documents & filings

Loading documents…

Peer comparison

Company	MCap (Cr)	Revenue	PAT	PE	PB	ROE%	ROCE%	D/E
Sun Pharmaceutical Industries Ltd.	4,40,794	58,462	11,565	38.4x	5.3x	16.2	19.9	0.03
Divi's Laboratories Ltd.	1,78,956	10,560	2,568	69.7x	10.7x	15.4	20.5	0
Torrent Pharmaceuticals Ltd.	1,49,820	13,980	2,138	69.3x	17.9x	26.8	19.3	1.76
Cipla Ltd.	1,09,370	28,163	3,870	28.2x	3.2x	11.8	16	0.01
Lupin Ltd.	1,07,537	27,958	5,355	20.2x	4.8x	21.1	22	0.3
Zydus Lifesciences Ltd.	1,06,823	27,148	5,026	21.2x	4x	21.1	26.1	0.13
Dr. Reddy's Laboratories Ltd.	1,06,133	33,700	4,144	25.3x	2.8x	18.6	23.3	0.14